Lonza and Crucell have entered into a co-exclusive manufacturing, sales and distribution agreement related to the Permexcis cell culture medium developed by Crucell for PER.C6 cells. Under this agreement, Lonza will manufacture the medium, and in addition will market and sell it on a global basis. Financial details of the agreement were not disclosed.

The Permexcis medium is a chemically defined cell culture medium that does not contain human- or animal-derived components. Permexcis medium was developed for the cultivation of PER.C6 cells and has been designed for use in the large-scale manufacture of biopharmaceutical products, including vaccines, according to a Crucell statement.

“We are pleased to have entered into this agreement with Lonza. The agreement demonstrates the power and robustness of our PER.C6 technology. Over 60 companies and organizations have already selected our PER.C6 technology to develop their own products across a wide range of therapeutic areas. We are proud that Lonza will manufacture the Permexcis cell culture medium and in addition will market and sell it globally” said Ronald Brus, Crucell’s chief executive officer.